X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-30 | RNTX | Rein Therapeutics, Inc. | Windsor James Brian | See Remarks | P - Purchase | $1.00 | +25,000 | 27,046 | >999% | +$25,000 | |||||
2026-05-11 | GNLX | Genelux Corp | Yu Yong | Chief Scientific Officer | S - Sale | $2.97 | -605 | 149,706 | 0% | -$1,798 | ||||||
2026-05-11 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $2.97 | -605 | 154,549 | 0% | -$1,799 | ||||||
2026-05-11 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $2.94 | -2,798 | 532,051 | -1% | -$8,226 | ||||||
2026-05-11 | GNLX | Genelux Corp | Smalling Ralph | Head of Regulatory | S - Sale | $2.98 | -270 | 67,803 | 0% | -$804 | ||||||
| M | 2026-05-08 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.69 | -407,574 | 1,171,175 | -26% | -$280,210 | |||||
| D | 2026-05-12 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $100.12 | -75,000 | 523,478 | -13% | -$7,509,000 | |||||
2026-05-11 | ZTS | Zoetis Inc. | McCallister Michael B | Dir | P - Purchase | $77.76 | +3,000 | 31,893 | +10% | +$233,273 | ||||||
| M | 2026-05-08 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $45.89 | -75,000 | 2,457,198 | -3% | -$3,441,958 | |||||
| M | 2026-05-08 | HOWL | Werewolf Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $0.69 | -565,167 | 406,282 | -58% | -$390,688 | |||||
| D | 2026-05-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $573.10 | -9,500 | 679,797 | -1% | -$5,444,417 | |||||
| D | 2026-05-11 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $573.03 | -10,000 | 18,876 | -35% | -$5,730,317 | |||||
| D | 2026-05-08 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $78.97 | -3,540 | 105,212 | -3% | -$279,570 | |||||
| D | 2026-05-08 | QURE | Uniqure N.V. | Abi-Saab Walid | Chief Medical Officer | S - Sale+OE | $25.06 | -45,000 | 169,669 | -21% | -$1,127,500 | |||||
2026-05-11 | AMRX | Amneal Pharmaceuticals, Inc. | Autor Deborah M. | Dir | S - Sale | $12.94 | -34,819 | 93,660 | -27% | -$450,558 | ||||||
2026-05-11 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | CFO | S - Sale | $25.63 | -7,763 | 84,161 | -8% | -$198,966 | ||||||
2026-05-11 | ASND | Ascendis Pharma A/S | Jensen Flemming Steen | See Remarks | S - Sale | $238.49 | -19,460 | 0 | -100% | -$4,641,021 | ||||||
2026-05-11 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $52.28 | -351 | 41,810 | -1% | -$18,350 | ||||||
2026-05-11 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $30.13 | -13,917 | 162,331 | -8% | -$419,263 | ||||||
| M | 2026-05-07 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $28.47 | -68,491 | 1,613,519 | -4% | -$1,949,634 | |||||
2026-05-07 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $28.54 | -4,438 | 346,059 | -1% | -$126,640 | ||||||
2026-05-07 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $28.28 | -721 | 242,729 | 0% | -$20,390 | ||||||
| DM | 2026-05-07 | PTGX | Protagonist Therapeutics, Inc | Giraudo Bryan | Dir | S - Sale+OE | $100.10 | -59,130 | 12,695 | -82% | -$5,918,880 | |||||
| D | 2026-05-07 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | COO | P - Purchase | $2.88 | +8,680 | 20,451 | +74% | +$24,998 | |||||
| D | 2026-05-07 | CLRB | Cellectar Biosciences, Inc. | Caruso James V | CEO | P - Purchase | $2.88 | +8,680 | 20,318 | +75% | +$24,998 | |||||
2026-05-07 | RCKT | Rocket Pharmaceuticals, Inc. | Chaudhuri Sarbani | See Remarks | S - Sale | $3.84 | -17,650 | 267,510 | -6% | -$67,741 | ||||||
| M | 2026-05-07 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $45.62 | -292,952 | 2,671,822 | -10% | -$13,364,065 | |||||
| M | 2026-05-07 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $45.62 | -292,952 | 2,671,822 | -10% | -$13,364,065 | |||||
2026-05-11 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $5.96 | -5,548 | 313,071 | -2% | -$33,073 | ||||||
| M | 2026-05-07 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $67.40 | -80,000 | 5,148,584 | -2% | -$5,392,243 | |||||
| M | 2026-05-07 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.12 | -276,513 | 7,401,933 | -4% | -$11,094,906 | |||||
2026-05-07 | BMRN | Biomarin Pharmaceutical Inc | Friberg Gregory R | EVP, Chief R, D Officer | S - Sale | $53.85 | -3,281 | 51,818 | -6% | -$176,682 | ||||||
| D | 2026-05-08 | DNTH | Dianthus Therapeutics, Inc. /De/ | Soteropoulos Paula | Dir | S - Sale+OE | $85.47 | -599 | 0 | -100% | -$51,197 | |||||
| D | 2026-05-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.95 | -9,500 | 679,797 | -1% | -$5,367,044 | |||||
| M | 2026-05-08 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.11 | +500,000 | 7,458,871 | +7% | +$56,391 | |||||
| D | 2026-05-07 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $24.12 | -18,606 | 423 | -98% | -$448,818 | |||||
2026-05-07 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $54.36 | -305 | 42,161 | -1% | -$16,580 | ||||||
| D | 2026-05-08 | MBX | Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | S - Sale+OE | $38.36 | -70,003 | 14,769 | -83% | -$2,685,515 | |||||
2026-05-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $30.00 | -10,000 | 134,985 | -7% | -$300,000 | ||||||
| D | 2026-05-07 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $578.58 | -10,000 | 18,876 | -35% | -$5,785,775 | |||||
| D | 2026-05-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $578.54 | -9,500 | 679,797 | -1% | -$5,496,084 | |||||
2026-05-08 | SYRE | Spyre Therapeutics, Inc. | Henderson Michael Thomas | Dir | S - Sale | $74.40 | -80,000 | 88,606 | -47% | -$5,952,050 | ||||||
2026-05-07 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $153.21 | -666 | 0 | -100% | -$102,039 | ||||||
2026-05-08 | TSSI | Zomedica Corp. | Heaton Larry C II | CEO | P - Purchase | $0.11 | +250,000 | 1,250,000 | +25% | +$27,500 | ||||||
2026-05-06 | MBX | Mbx Biosciences, Inc. | Azoulay Salomon | Chief Medical Officer | S - Sale | $29.54 | -231 | 14,769 | -2% | -$6,824 | ||||||
2026-05-06 | MBX | Mbx Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO | S - Sale | $29.54 | -607 | 1,214,444 | 0% | -$17,931 | ||||||
2026-05-06 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $31.25 | -9,600 | 93,640 | -9% | -$300,043 | ||||||
| M | 2026-05-05 | GYRE | Gyre Therapeutics, Inc. | Luo Ying | CEO | S - Sale | $8.04 | -10,315 | 2,565,226 | 0% | -$82,927 | |||||
| M | 2026-05-05 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $54.61 | -18,608 | 72,992 | -20% | -$1,016,228 | |||||
| M | 2026-05-05 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.64 | -100,581 | 1,578,749 | -6% | -$64,217 | |||||
| M | 2026-05-05 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $40.99 | -75,000 | 2,532,198 | -3% | -$3,074,300 | |||||
| D | 2026-05-07 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $586.75 | -8,300 | 45,172 | -16% | -$4,870,054 | |||||
| D | 2026-05-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $589.52 | -9,500 | 679,797 | -1% | -$5,600,468 | |||||
| D | 2026-05-05 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $51.83 | -20,000 | 2,231 | -90% | -$1,036,600 | |||||
| D | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Varki Paul | GC | S - Sale+OE | $20.17 | -75,063 | 3,634 | -95% | -$1,513,673 | |||||
| D | 2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | CFO | S - Sale+OE | $20.19 | -47,000 | 423 | -99% | -$948,722 | |||||
| DM | 2026-05-05 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.61 | -108,234 | 3,622 | -97% | -$2,230,367 | |||||
2026-05-06 | AVTX | Avalo Therapeutics, Inc. | Chan Mitchell | Dir | S - Sale | $22.88 | -3,167 | 3,166 | -50% | -$72,461 | ||||||
2026-05-06 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $153.84 | -1,000 | 666 | -60% | -$153,839 | ||||||
2026-05-06 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale | $36.00 | -10,679 | 20,016 | -35% | -$384,444 | ||||||
2026-05-05 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $54.99 | -1,207 | 42,820 | -3% | -$66,373 | ||||||
2026-05-05 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, Europe Commercial | S - Sale | $35.40 | -30,000 | 55,755 | -35% | -$1,062,000 | ||||||
| A | 2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | SVP, Corporate Controller | S - Sale | $13.35 | -26,448 | 0 | -100% | -$353,080 | |||||
2026-05-06 | LLY | Eli Lilly & Co | Lilly Endowment Inc | Former 10% Shareholder | S - Sale | $995.36 | -15,828 | 91,881,150 | 0% | -$15,754,537 | ||||||
2026-05-06 | OGN | Organon & Co. | Holzbaur Lynette | SVP, Corporate Controller | P - Purchase | $13.35 | +26,448 | 52,851 | +100% | +$353,080 | ||||||
2026-05-04 | SPRO | Spero Therapeutics, Inc. | Rajavelu Esther | See Remarks | S - Sale | $2.51 | -25,240 | 986,851 | -2% | -$63,352 | ||||||
| M | 2026-05-04 | RLYB | Rallybio Corp | Adar1 Capital Management, LLC | 10% | P - Purchase | $13.97 | +155,905 | 779,784 | +25% | +$2,178,668 | |||||
| M | 2026-04-28 | TLX | Telix Pharmaceuticals Ltd | Behrenbruch Christian | MD, Group CEO | P - Purchase | $14.67 | +67,935 | 20,742,935 | 0% | +$996,738 | |||||
| M | 2026-05-04 | MPLT | Maplight Therapeutics, Inc. | Setia Vishwas | CFO | S - Sale | $28.17 | -36,371 | 356,256 | -9% | -$1,024,719 | |||||
| M | 2026-05-04 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $28.39 | -50,280 | 350,497 | -13% | -$1,427,594 | |||||
| M | 2026-05-04 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $28.40 | -51,707 | 243,450 | -18% | -$1,468,251 | |||||
2026-05-04 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $27.89 | -13,917 | 176,248 | -7% | -$388,177 | ||||||
| M | 2026-05-04 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $28.39 | -49,744 | 1,682,010 | -3% | -$1,412,236 | |||||
| D | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $46.65 | -4,500 | 37,500 | -11% | -$209,925 | |||||
| D | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Meckler Jeffrey A | Dir | S - Sale+OE | $45.00 | -8,000 | 87,500 | -8% | -$360,000 | |||||
| D | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | Rote William E. | Chief Research Officer | S - Sale+OE | $43.95 | -2,763 | 115,474 | -2% | -$121,434 | |||||
| DM | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $45.06 | -24,250 | 105,211 | -19% | -$1,092,657 | |||||
| DM | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale+OE | $45.15 | -22,485 | 113,238 | -17% | -$1,015,086 | |||||
| D | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale+OE | $46.65 | -2,174 | 140,684 | -2% | -$101,417 | |||||
| D | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $43.95 | -22,500 | 432,886 | -5% | -$988,875 | |||||
| DM | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $46.31 | -2,491 | 118,658 | -2% | -$115,368 | |||||
2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $23.31 | -8,256 | 126,689 | -6% | -$192,415 | ||||||
2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $23.61 | -684 | 120,466 | -1% | -$16,150 | ||||||
2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | SVP CFO | S - Sale | $23.61 | -1,341 | 86,413 | -2% | -$31,662 | ||||||
2026-05-04 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $23.61 | -3,172 | 953,889 | 0% | -$74,893 | ||||||
| D | 2026-05-04 | IONS | Ionis Pharmaceuticals Inc | Loscalzo Joseph | Dir | S - Sale+OE | $75.06 | -77,289 | 36,330 | -68% | -$5,801,226 | |||||
2026-05-05 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | SVP Operations | S - Sale | $55.32 | -346 | 44,334 | -1% | -$19,141 | ||||||
| M | 2026-05-04 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $18.14 | -106,723 | 1,136,810 | -9% | -$1,936,341 | |||||
| D | 2026-05-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $576.24 | -9,500 | 679,797 | -1% | -$5,474,240 | |||||
| D | 2026-05-04 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $101.69 | -30,000 | 324,879 | -8% | -$3,050,712 | |||||
2026-05-05 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $155.50 | -1,000 | 1,666 | -38% | -$155,502 | ||||||
| D | 2026-05-04 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $137.34 | -10,699 | 535,109 | -2% | -$1,469,442 | |||||
2026-05-04 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $5.82 | -806 | 612,113 | 0% | -$4,691 | ||||||
2026-05-05 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | EVP, Chief Medical Officer | S - Sale | $24.96 | -344 | 111,189 | 0% | -$8,586 | ||||||
| DM | 2026-05-04 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | COO | S - Sale+OE | $227.95 | -4,750 | 0 | -100% | -$1,082,771 | |||||
2026-05-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $22.99 | -7,144 | 32,600 | -18% | -$164,220 | ||||||
2026-05-05 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $16.60 | -14,055 | 37,592 | -27% | -$233,319 | ||||||
| D | 2026-05-01 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $21.23 | -27,000 | 115,743 | -19% | -$573,097 | |||||
| D | 2026-05-04 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $21.79 | -1,332 | 29,129 | -4% | -$29,024 | |||||
| D | 2026-05-04 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $21.79 | -3,506 | 66,145 | -5% | -$76,396 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |